Cost-effectiveness analysis of escalating to natalizumab or switching among immunomodulators in relapsing-remitting multiple sclerosis in Italy

Table 2 Disability-related costs (direct and indirect). Elaborated from [1]

Type of disease/type of cost	EDSS 0 (€)	EDSS 1 (€)	EDSS 2 (€)	EDSS 3 (€)	EDSS 4 (€)	EDSS 5 (€)	EDSS 6 (€)	EDSS 7 (€)	EDSS 8–10 (€)
RRMS direct	201	201	201	636	636	636	636	5708	5708
RRMS indirect	1143	1143	1143	11,847	11,847	11,847	11,847	28,411	28,411
SPMS direct	5331	5331	5331	18,894	18,894	18,894	18,894	9589	9589
SPMS indirect	4096	4096	4096	31,559	31,559	31,559	31,559	64,948	64,948

RRMS 0–6: only costs for co-medications. Not included the costs for DMTs and other disease management costs (e.g., administration, monitoring, etc.) considered in other calculation sections of the model. EDSS: expanded disability status scale. RRMS: relapsing-remitting multiple sclerosis. SPMS: secondary progressive multiple sclerosis. Direct costs include only the healthcare direct costs. The non-healthcare direct costs were included among the indirect costs

ISSN: 1472-6963